Bright Biotech
Bright Biotech is a UK-based biotechnology company that produces high-quality, animal-free recombinant growth factors (rhTGF-β3, rhFGF2) using a proprietary plant chloroplast expression platform, serving the cell culture, regenerative medicine, and cultivated meat markets.
- Company typePrivate
- Founded2022
- HeadquartersManchester, United Kingdom
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What Bright Biotech does
Bright Biotech is a UK-based biotechnology company that develops and manufactures recombinant proteins using a proprietary plant chloroplast expression platform for the life sciences and food sectors. The company's Green2Screen™ transformation technology inserts value-added genes into chloroplast DNA, then uses only CO2, salts, water, and light to grow the host plants, harvesting and purifying the expressed proteins to deliver high-activity, high-purity (>95%), animal-free, endotoxin-free, and tag-free recombinant growth factors at yields of 2-5 g of protein per kg of leaf biomass, with 10,000-fold amplification achievable through seed-based propagation.
The company currently markets two named SKUs — Recombinant Human Transforming Growth Factor Beta 3 (rhTGF-β3) and Recombinant Human Fibroblast Growth Factor 2 (rhFGF2) — for cell culture, regenerative medicine, and cultivated meat applications, where it positions its offering as a solution to the 55-95% cell-culture media cost bottleneck. On top of the same platform, the company offers custom and species-specific protein production (enzymes, antibodies, hormones), with manufacturing capacity currently in the hundreds-of-milligrams range and a stated roadmap to gram and kilogram quantities. The team of approximately 12 named members is led by Mohammad El Hajj, with Anil Day serving as CTO and recognised leadership in chloroplast biotechnology, and draws on more than 60 years of combined experience across institutions including UCL, University of Tennessee, University of Cambridge, MIT, MRC Laboratory of Molecular Biology, and the Quadram Institute.
Revenue is generated through direct product sales of the two growth factor SKUs and custom protein production services, with enquiry-based contact via a general [email protected] mailbox and no public pricing, distribution partners, or named customer logos disclosed. To date, the company has raised a $3.2 million seed round in November 2022 (led by FoodLabs with Big Idea Ventures, CPT Capital, HackCapital, and FoodHack) and £1 million in Phase One funding from ARIA's Synthetic Plants programme in August 2025, and is registered as a private limited company headquartered in Manchester, England.
Bright Biotech firmographics
Firmographics- Name
- Bright Biotech
- Legal name
- Bright Biotech
- Website
- https://brightbiotech.co.uk
- Company type
- Private
- Founded year
- 2022
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Bright Biotech is a UK-based biotechnology company that produces high-quality, animal-free recombinant growth factors (rhTGF-β3, rhFGF2) using a proprietary plant chloroplast expression platform, serving the cell culture, regenerative medicine, and cultivated meat markets.
- Ownership category
- akta.pro rank
Bright Biotech industry classification
Industry- Product category
- Recombinant Protein Manufacturing
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Cell Culture Media & Growth Factor Suppliers (Food-Grade) (AFANAKAD)
- akta.pro secondary industry
- Fermentation-Derived Alternative Proteins Manufacturing (Precision Fermentation) (AFAKAGAH)
Keywords
Where Bright Biotech is headquartered
LocationHeadquarters
- HQ city
- Manchester
- HQ country
- United Kingdom
- HQ region
- Europe
Markets served
Bright Biotech business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain
Bright Biotech product offering
Product offeringCore offering
Bright Biotech develops and manufactures high-quality, affordable recombinant proteins using a proprietary plant chloroplast-based expression platform (Green2Screen™ transformation). Its current commercial catalogue consists of two recombinant human growth factors — rhTGF-β3 and rhFGF2 — sold as high-purity (>95%), animal-free, endotoxin-free, tag-free reagents for cell culture, regenerative medicine, and cultivated meat applications. Custom and species-specific protein production (enzymes, antibodies, hormones) is also offered on the same platform.
Product overview
Bright Biotech operates a single integrated chloroplast-based protein production platform, powered by its proprietary Green2Screen™ transformation technology, that produces the company's named recombinant growth factor products. The platform underlies the two currently listed SKUs — Recombinant Human Transforming Growth Factor Beta 3 (rhTGF-β3) and Recombinant Human Fibroblast Growth Factor 2 (rhFGF2) — which are sold for cell culture, regenerative medicine, and cultivated meat applications. Custom and species-specific protein production (enzymes, antibodies, hormones) is offered on top of the same platform, with manufacturing capacity currently in the hundreds-of-milligrams range and a roadmap to gram and kilogram quantities.
Differentiator
Problem solved
Functional benefit
Products and services
- Recombinant Human Transforming Growth Factor Beta 3 (rhTGF-β3) Recombinant human TGF-β3 growth factor produced via Bright Biotech's chloroplast-based expression platform. Marketed as a high activity, high purity (>95%), animal-free, endotoxin-free, and tag-free protein intended for cell culture and regenerative medicine applications. PDS and MSDS documentation is available for download.
- Recombinant Human Fibroblast Growth Factor 2 (rhFGF2) Recombinant human FGF2 growth factor manufactured using Bright Biotech's chloroplast expression system. Part of the company's named growth factor portfolio for cell culture and regenerative medicine, complementing rhTGF-β3 in the catalogue.
- Custom and Species-Specific Protein Production Custom recombinant protein production service covering enzymes, antibodies, hormones, and species-specific proteins, delivered via Bright Biotech's chloroplast-based expression platform. Targeted at life science and food sector customers with specific protein production needs.
Companies that use Bright Biotech
Customer profileIdeal customer profiles3 records
Bright Biotech technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Bright Biotech partnerships and signals
Strategic signalRecent moves6 records
Expansion highlights6 records
Bright Biotech competitors and assessment
Company assessmentDirect peers
- Bio-Techne: Bio-Techne (R&D Systems brand) is a leading global manufacturer of recombinant growth factors and cytokines for cell culture, regenerative medicine, and research. It is the most direct incumbent competing against Bright Biotech in the recombinant growth factor market that Bright Biotech targets with its chloroplast-based rhTGF-β3 and rhFGF2.
- CellGenix: CellGenix manufactures GMP-grade recombinant growth factors and cytokines for cell and gene therapy manufacturing. It is a direct comparable to Bright Biotech in the same recombinant growth factor product category and shares the same regenerative-medicine and cell-therapy end-customer base.
Broad incumbents
- PeproTech (Thermo Fisher Scientific): PeproTech, now part of Thermo Fisher Scientific, is a long-established manufacturer of recombinant growth factors, cytokines, and cell-culture reagents. It is comparable to Bright Biotech as a competing supplier of the same rhTGF-β3, rhFGF2, and adjacent growth factor SKUs that Bright Biotech lists in its catalogue.
- Miltenyi Biotec: Miltenyi Biotec supplies cell-culture media, recombinant proteins, and cell-therapy manufacturing reagents. It overlaps with Bright Biotech across cell-culture reagents and growth factors used in regenerative medicine and cell therapy workflows.
- Cytiva (Danaher): Cytiva supplies cell-culture media, growth factors, and bioprocessing tools to the cell-therapy, gene-therapy, and biopharmaceutical industries. It is comparable to Bright Biotech as a broad supplier of cell-culture reagents and growth factors serving the same regenerative-medicine customer base.
- Lonza Group: Lonza is a global contract development and manufacturing organisation with cell-culture media, recombinant protein production, and cell-therapy manufacturing offerings. It is comparable to Bright Biotech as a large-scale incumbent supplying recombinant growth factors and cell-culture products to the same life-sciences and cultivated-meat end markets.
Emerging players
- Leaf Expression Systems: Leaf Expression Systems is a UK-based plant-based protein expression company that uses transient expression in Nicotiana benthamiana. It is comparable to Bright Biotech as another UK-headquartered, plant-based recombinant-protein manufacturer pursuing similar customer use cases in life sciences.
- Planet Biotechnology: Planet Biotechnology uses transgenic plant expression to produce recombinant antibodies, enzymes, and other proteins. It is a comparable plant-based recombinant-protein manufacturer to Bright Biotech, sharing the same core proposition of using plants as bioreactors for high-value proteins.
- Biftek: Biftek is a startup producing low-cost growth factors specifically for the cultivated-meat industry using precision fermentation. It is a direct comparable to Bright Biotech's cultivated-meat growth-factor business because it competes head-to-head on the same problem (growth factor cost) using a different production modality.
- iBIO Inc: iBIO uses plant-based expression systems (including transient and stable plant platforms) for the development and manufacturing of recombinant proteins and vaccines. It overlaps with Bright Biotech in using plant-based manufacturing for high-value recombinant proteins targeting life-sciences and biopharma customers.
Market position
Strengths5 records
Weaknesses4 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Bright Biotech social profiles
Digital presenceBright Biotech compliance and trust
Trust signalCompliance1 record
Bright Biotech financial estimates
Financial estimateRevenue estimate
Valuation estimate
Bright Biotech leadership team
Management profileNumber of profiles
Profiles12 records
Bright Biotech funding detail
Funding detailFunding overview
Funding rounds2 records
Investors6 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Bright Biotech M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Bright Biotech
What does Bright Biotech do?
Bright Biotech develops and manufactures high-quality, affordable recombinant proteins using a proprietary plant chloroplast-based expression platform (Green2Screen™ transformation). Its current commercial catalogue consists of two recombinant human growth factors — rhTGF-β3 and rhFGF2 — sold as high-purity (>95%), animal-free, endotoxin-free, tag-free reagents for cell culture, regenerative medicine, and cultivated meat applications. Custom and species-specific protein production (enzymes, antibodies, hormones) is also offered on the same platform.
Is Bright Biotech a public or private company?
Bright Biotech is a private company. It is classified as venture growth investor backed and is currently operating.
When was Bright Biotech founded?
Bright Biotech was founded in 2022. It employs 1 to 10 people.
Where is Bright Biotech based?
Bright Biotech is headquartered in Manchester, United Kingdom, in the Europe region.
Who are Bright Biotech's main competitors?
Direct peers on record are Bio-Techne and CellGenix. Broad incumbents are PeproTech (Thermo Fisher Scientific), Miltenyi Biotec, Cytiva (Danaher) and Lonza Group. Emerging players are Leaf Expression Systems, Planet Biotechnology, Biftek and iBIO Inc.
Does Bright Biotech have an API?
No public API is recorded for Bright Biotech.
What industry is Bright Biotech in?
Bright Biotech's product category is Recombinant Protein Manufacturing. Its primary akta.pro industry code is AFANAKAD, Cell Culture Media & Growth Factor Suppliers (Food-Grade), with a secondary code of AFAKAGAH, Fermentation-Derived Alternative Proteins Manufacturing (Precision Fermentation). Its NAICS code is 325414 and its SIC code is 2836.